Crohn's Disease Clinical Trials

All subjects in the study will have had loss of response or intolerance to conventional medication used to treat Crohn’s disease.

The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or do not meet protocol response or remission criteria at ...

This is a multicenter, Phase III, double-blind, placebo-controlled study evaluating the safety and efficacy of etrolizumab during induction and maintenance treatment of moderate to severely active Crohn's disease (CD) in patients who are anti-tumor necrosis factor (TNF) naive (TNF-naive) and in patients who are refractory or intolerant of tumor necrosis ...

The primary objective of this study is to evaluate the efficacy of filgotinib as compared to placebo in establishing combined fistula response at Week 24. Participants will have the option to enter a separate long-term extension study if they meet eligibility requirements.

The primary objective of this study is to evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission in participants with Crohn's disease involving the small bowel. Participants will have the option to enter a separate long-term extension study if they meet eligibility requirements.

A study to evaluate the safety and efficacy of an investigational drug in subjects with moderate to severe Crohn's disease. REF: 001-CGI

This is a multicenter, Phase III, double-blind, placebo-controlled study evaluating the safety and efficacy of etrolizumab during induction and maintenance treatment of moderate to severely active Crohn's disease (CD) in patients who are anti-tumor necrosis factor (TNF) naive (TNF-naive) and in patients who are refractory or intolerant of tumor necrosis ...

If you are living with Crohn’s, our clinical research study may be for you. Our team of medical professionals is evaluating an oral investigational drug called filgotinib to see if it reduces the signs and symptoms of Crohn’s disease by lowering the immune response that causes inflammation in the digestive ...

You are being asked to take part in this study because you have been diagnosed with Crohn’s Disease (CD). The purpose of this research study is to determine whether CROWN, an orally administered nutritional intervention and the study product under investigation works (is effective) to help improve your bowel health ...

Join a clinical research study of Crohn’s disease. Wake Research Associates is enrolling volunteers with Crohn’s disease in a study evaluating the effectiveness of a nutritional intervention in improving bowel health when combined with usual medical care.